Latest Public Health News

Moab Minerals reports robust uranium mineralisation from its Manyoni Project in Tanzania and progresses exploration in Colorado’s Uravan Belt, supported by a recent $500k capital raise.

4DMedical Limited reports a 103% surge in year-to-date revenue, secures major contracts with leading healthcare providers, and advances its CT:VQ™ technology towards FDA clearance.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

TruScreen has launched a landmark five-year cervical cancer screening program in Ho Chi Minh City, targeting 260,000 women with its AI-driven, non-invasive technology to boost screening rates and support Vietnam’s national health goals.

Smartgroup has been appointed as the exclusive provider of salary packaging and novated leasing services for Monash Health’s 25,000 employees under a new multi-year contract starting April 2025.

Bio-Gene Technology Limited has secured A$3 million in U.S. Department of Defense grants to accelerate development of its two nature-derived insecticides, Flavocide and Qcide, targeting both military and civilian markets.

Skin Elements Limited reports steady progress in commercialising its plant-based SE Formula biotechnology, highlighted by ongoing product trials, a successful R&D rebate, and a $513k non-renounceable entitlement issue.

Advanced Health Intelligence Ltd has locked in a USD$4 million convertible note facility with UAE-based KOR Investments LLC, aiming to raise up to AUD$10 million to fuel its MENA expansion and reduce debt.

Unith Ltd has reported its strongest quarterly revenue in two years, driven by its B2C subscription division and strategic partnerships, while advancing its Digital Human technology and expanding into new markets.

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Bio-Gene Technology Limited has been awarded two U.S. Department of Defense grants totaling A$3 million to develop innovative insect control products targeting military and civilian markets.